Gainers
- Polyrizon (NASDAQ:PLRZ) stock increased by 16.6% to $1.69 during Tuesday's after-market session. The company's market cap stands at $4.8 million.
- Strata Skin Sciences (NASDAQ:SSKN) stock rose 7.94% to $2.31. The company's market cap stands at $9.2 million.
- Equillium (NASDAQ:EQ) shares increased by 7.47% to $0.42. The market value of their outstanding shares is at $14.7 million.
- Celularity (NASDAQ:CELU) shares moved upwards by 5.88% to $3.96. The company's market cap stands at $75.4 million.
- Contineum Therapeutics (NASDAQ:CTNM) stock moved upwards by 5.57% to $5.45. The company's market cap stands at $146.1 million.
- Stoke Therapeutics (NASDAQ:STOK) shares increased by 4.64% to $14.2. The market value of their outstanding shares is at $672.0 million.
Losers
- Know Labs (AMEX:KNW) shares decreased by 7.3% to $2.3 during Tuesday's after-market session. The company's market cap stands at $17.8 million.
- Molecular Partners (NASDAQ:MOLN) stock fell 6.92% to $3.5. The market value of their outstanding shares is at $141.9 million.
- GRI Bio (NASDAQ:GRI) stock fell 5.8% to $1.92. The company's market cap stands at $4.9 million.
- Nanoviricides (AMEX:NNVC) stock decreased by 5.3% to $1.61. The company's market cap stands at $27.1 million.
- IGC Pharma (AMEX:IGC) stock fell 4.79% to $0.39. The market value of their outstanding shares is at $29.4 million.
- Monte Rosa Therapeutics (NASDAQ:GLUE) stock fell 4.78% to $5.38. The market value of their outstanding shares is at $358.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
CTNMContineum Therapeutics Inc
$11.93-%
EQEquillium Inc
$1.27-0.77%
GLUEMonte Rosa Therapeutics Inc
$10.16-2.31%
GRIGRI Bio Inc
$1.81-2.16%
IGCIGC Pharma Inc
$0.3811-3.00%
MOLNMolecular Partners AG
$3.77-0.53%
NNVCNanoviricides Inc
Not Available-%
PLRZPolyrizon Ltd
$1.18-%
SSKNStrata Skin Sciences Inc
$1.561.30%
STOKStoke Therapeutics Inc
$30.00-1.12%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.